| 501 |
15857287 | Small molecules with EGFR-TK inhibitor activity. | 2005 May |
1 |
| 502 |
15955900 | Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. | 2005 Aug 10 |
2 |
| 503 |
16091755 | Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. | 2005 Sep 15 |
3 |
| 504 |
22500146 | Lapatinib: the evidence for its therapeutic value in metastatic breast cancer. | 2005 |
1 |
| 505 |
14737100 | Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. | 2004 Jan 22 |
3 |
| 506 |
14751502 | Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. | 2004 Feb 1 |
4 |
| 507 |
14967461 | Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. | 2004 Mar 1 |
1 |
| 508 |
15163842 | Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. | 2004 |
2 |
| 509 |
15374980 | A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. | 2004 Sep 15 |
11 |
| 510 |
12964069 | Lapatinib ditosylate GlaxoSmithKline. | 2003 Sep |
1 |
| 511 |
12214266 | Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. | 2002 Sep 12 |
6 |